European Biotech Acquisition Corp. (EBAC)
| Market Cap | 159.72M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 13.21M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | - |
| Open | - |
| Previous Close | 9.69 |
| Day's Range | 9.74 - 9.76 |
| 52-Week Range | 9.59 - 10.48 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | n/a |
About EBAC
European Biotech Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2021 and is based in Amsterdam, the Netherlands.
News
European Biotech Acquisition Corp. Receives Expected Notification from Nasdaq Related to Delayed Quarterly Report
NEW YORK--(BUSINESS WIRE)--European Biotech Acquisition Corp. receives expected notification from Nasdaq related to delayed quarterly report.
CORRECTING and REPLACING European Biotech Acquisition Corp. Announces Pricing of Upsized $120 Million Initial Public ...
European Biotech Acquisition Corp. (the “Company”) announced today that it priced its initial public offering of 12,000,000 units at $10.00 per unit.
Eduardo Bravo returns to bring European biotech in on the SPAC splurge
The last year’s SPAC boom has been dominated so far by US-based VCs. Now a prominent European biotech executive and a couple investors are getting in on the game.
Life sciences SPAC European Biotech Acquisition files for a $100 million IPO
European Biotech Acquisition, a blank check company formed by LSP targeting the life sciences industry in Europe, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering.
European Biotech Acquisition IPO Registration Document (S-1)
European Biotech Acquisition Corp. has filed to go public with an IPO on the NASDAQ.